ClinicalTrials.gg
RecruitingNCT06835491PARACAUpdated Dec 23, 2025

Prophylactic Anti-aRrhythmic Therapy With Amiodarone in Critically Ill Patients Admitted for an Out-of-hospital Cardiac Arrest With Initial Shockable Rhythm

A Phase 3 interventional study of Amiodarone in Ventricular Arrhythmias and Cardiac Arrest, sponsored by Versailles Hospital. Recruiting at 29 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Versailles Hospital · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
674
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Heart Arrest with a site in France — 32 open to participants now, 33 under way, 3 of them phase 3. Heart Arrest · France.

Planned enrollment
13th of 59
674 · median 106
Started
2025
with 9 others
Phase 3
13 of 106
3 open now
Primary completion
2027-01
later than 12 of 32 live
Registered
93rd of 106
by date

Among the 106 studies in Heart Arrest with a site in France, this one is the 13th largest by planned enrollment of the 59 interventional ones that give a count, is one of 10 that started in 2025, is one of 13 in phase 3, reaches primary completion later than 12 of the 32 other live ones, and was the 93rd registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

32 of the 106 studies in Heart Arrest with a site in France are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Heart Arrest with a site in France, or all of them as a file.
02

Study summary

To determine if prophylactic administration of amiodarone for 72 hours in critically ill patients admitted after an OHCA with shockable rhythm, with a confirmed or a presumed cardiac cause, decreases the incidence of a composite endpoint of 30-day (starting from inclusion) all-cause mortality and/or severe in-hospital ventricular arrhythmia recurrence (ventricular fibrillation and/or ventricular tachycardia requiring intervention including re-arrest)

03

Conditions studied

  • Ventricular Arrhythmias and Cardiac Arrest

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient aged ≥ 18 years
  2. Admitted in intensive care unit
  3. Out-of-hospital cardiac arrest with initial shockable rhythm
  4. Presumed cardiac or unknown cause
  5. Delay between ROSC and screening for randomisation \< 6 hours
  6. from the patient or a surrogate or deferred consent
  7. Affiliated to or benefiting from a social insurance

Exclusion criteria

Exclusion Criteria:

  1. Cardiac arrest secondary to an extra-cardiac cause (suspected or confirmed)
  2. Indication for amiodarone decided by the physician at ICU admission
  3. No central venous catheter available for continuous infusion of amidoarone
  4. Thyroid disease under treatment
  5. History of cardiac conduction disorders, not treated by permanent pacemaker
  6. Any contra indication to amiodarone treatment
  7. ventricular arrhythmia or electrical storm
  8. Need for veno-arterial extracorporeal membrane oxygenation (VA-ECMO) at admission
  9. Known limitations in therapy and Do Not Resuscitate-order
  10. Moribund patient due to pre-arrest history (estimated \< 3 months)
  11. Pregnant or breastfeeding women
  12. Patient needing a nadolol treatment due to long syndrome or catecholaminergic polymorphic ventricular tachycardia
  13. Patient with known pulmonary fibrosis
  14. Patient with known interstitial lung disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
674 participants (estimated)

Study arms

  • Experimental
    Amiodarone

    Initial loading dose of 300mg over 30 minutes in 250ml of glucose 5% solution. Continuous amiodarone infusion will be administered for 72 hours at a dose of 10 mg/kg without exceeding 900 mg/24h.

    Drug: Amiodarone

  • No intervention
    Control

Interventions

  • Initial loading dose of 300mg over 30 minutes in 250ml of glucose 5% solution. Continuous amiodarone infusion will be administered for 72 hours at a dose of 10 mg/kg without exceeding 900 mg/24h.

06

What researchers measure

Primary outcomes

  1. Rate of Mortality and severe ventricular arrhythmia

    The primary endpoint is a composite of 30-day (starting from inclusion) all-cause mortality and occurrence of severe in-hospital ventricular arrhythmia, defined by ventricular fibrillation and/or ventricular tachycardia requiring intervention occurring between inclusion and hospital discharge (or 30-day whichever the sooner).

    Time frame: 30 days

Secondary outcomes

  1. outcomes related with cardiac events

    * Occurrence of ventricular fibrillation (VF) * Occurrence of ventricular tachycardia (VT) requiring or not intervention * Occurrence of atrial fibrillation (AF) and supraventricular tachycardia * Occurrence of cardiac re-arrest due to asystole

    Time frame: 90 days

  2. outcomes related with mortality

    * ICU mortality * Hospital (and 30-day) mortality * Day 90 mortality

    Time frame: 90 days

  3. Duration of invasive mechanical ventilation

    Time frame: 90 days

  4. Number of participants with outcomes related with amiodorane side effects

    Number of the following side effects, patients could experimente (if applicable) during amiodarone infusion: * Conduction disorders * Hemodynamic consequences * Hepatic cytolysis * Anaphylaxis

    Time frame: 5 days

  5. Neurological outcome

    M-Rankin scale (the lowest score is no handicap and the highest score is death) and Glasgow Outcome Score (the lowest score is the most severe coma)

    Time frame: 90 days

  6. Duration vasopressor infusion

    Time frame: 90 days

  7. Length of ICU stay

    Time frame: 90 days

  8. Length of stay in hospital

    Time frame: 90 days

  9. Dose of the anti-arrhythmic drugs

    Time frame: 90 days

  10. Number of days of anti-arrhythmic drugs

    Time frame: 90 days

07

Study locations

25 of 29 sites recruiting
  • Chu Amiens
    Amiens, France
    Not yet recruiting
    • julien maizel, md · Contact
  • Chu Angers
    Angers, France
    Recruiting
    • pierre asfar, MD · Contact
  • CH annecy genevois
    Annecy, France
    Recruiting
    • davis bougon, md · Contact
  • Ch Argenteuil
    Argenteuil, France
    Recruiting
    • gaetan plantefeve, md · Contact
  • CH Mondor
    Aurillac, France
    Recruiting
    • Emanuele turbil, MD · Contact
  • CHU Brest
    Brest, France
    Recruiting
    • pierre bailly, MD · Contact
  • CH Brive
    Brive-la-Gaillarde, France
    Recruiting
    • cédric barucchi, MD · Contact
  • Chu Caen
    Caen, France
    Not yet recruiting
    • cédric daubin, MD · Contact
  • Chi Nord Ardennes
    Charleville-Mézières, France
    Recruiting
    • jérémy rosman, MD · Contact
  • CHSF
    Corbeil-Essonnes, France
    Recruiting
    • sophie marques, md · Contact
  • CHD vendée
    La Roche-sur-Yon, France
    Recruiting
    • gwenhael colin, MD · Contact
  • CH la rochelle
    La Rochelle, France
    Recruiting
    • francois perrier, MD · Contact
  • Hcl
    Lyon, France
    Recruiting
    • jean christophe richard, MD · Contact
  • Ap Hm
    Marseille, France
    Recruiting
    • jeremy bourenne · Contact
  • Hopital Cartier
    Massy, France
    Recruiting
    • wulfran bougouin, md · Contact
  • chi Gregoire
    Montreuil, France
    Not yet recruiting
    • vincent das, MD · Contact
  • Hoptial Mulhouse
    Mulhouse, France
    Recruiting
    • guylaine labro, md · Contact
  • CHU Nantes
    Nantes, France
    Not yet recruiting
    • jean baptiste lascarrou, MD · Contact
  • Clinique Ambroise Paré
    Neuilly-sur-Seine, France
    Recruiting
    • guillaume geri, md · Contact
  • CHU Nice -MIR Archet
    Nice, France
    Recruiting
    • mathieu jozwiak · Contact
  • CHU Nice -MIR Pasteur
    Nice, France
    Recruiting
    • denis doyen, MD · Contact
  • Chu Orléans
    Orléans, France
    Recruiting
    • grégoire muller, MD · Contact
  • CHU Cochin
    Paris, France
    Recruiting
    • alain coriou, MD · Contact
  • Hopital saint joseph
    Paris, France
    Recruiting
    • cedric bruel, MD · Contact
  • CHU Poitiers
    Poitiers, France
    Recruiting
    • florence boissier, MD · Contact
  • Chu Strasbourg
    Strasbourg, France
    Recruiting
    • antoine studer, md · Contact
  • CHI Toulon
    Toulon, France
    Recruiting
    • noemie peres, MD · Contact
  • Chu Toulouse
    Toulouse, France
    Recruiting
    • clement delmas, md · Contact
  • CH Cotentin
    Valognes, France
    Recruiting
    • julien calus, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Jan 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2025
First posted
Feb 19, 2025
StartActual
Nov 6, 2025
Primary completionEst.
Jan 15, 2027
CompletionEst.
Mar 15, 2027
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06835491
Lead sponsor
Versailles Hospital
Responsible party
Hugo Bellut (Investigator coordonator, Versailles Hospital) — Principal investigator
First posted
Feb 19, 2025
Start date
Nov 6, 2025
Primary completion
Jan 15, 2027 (estimated)
Completion
Mar 15, 2027 (estimated)
Last update
Dec 23, 2025

Study contacts

Sandrine Roux
Contact
sroux@ght78sud.fr
0139239777

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amiodarone

Start the discussion